Revelation Biosciences, Inc. (REVB)

1.5300 +0.1600 (+11.68%) At close: 04:00PM EDT

Revelation Biosciences, Inc.

4660 La Jolla Village Drive
Suite 100
San Diego, CA 92122
United States
650 800 3717
https://www.revbiosciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 14

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. James M. Rolke	CEO & Director	466.63k	N/A	1969
Mr. Chester Stanley Zygmont III	CFO & Corp. Sec.	366.64k	N/A	1980
Ms. Sandra Vedrick	VP of HR & Investor Relations	N/A	N/A	N/A
Ms. Carol Odle	Sr. Director of Clinical Projects	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Corporate Governance

Revelation Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.